CARDENE SR drug interactions: Difference between revisions
(Created page with "__NOTOC__ {{Nicardipine}} {{CMG}}; {{AE}}:{{AK}} '''''For patient information about Nicardipine, click here.''''' ==Drug Interactions==...") |
No edit summary |
||
| Line 17: | Line 17: | ||
'''Cyclosporine:''' Concomitant administration of nicardipine and [[cyclosporine]] results in elevated plasma cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine. | '''Cyclosporine:''' Concomitant administration of nicardipine and [[cyclosporine]] results in elevated plasma cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine. | ||
When therapeutic concentrations of [[furosemide]], [[propranolol]], [[dipyridamole]], [[warfarin]], [[quinidine]] or [[naproxen]] were added to human plasma (in vitro), the plasma protein binding of CARDENE was not altered. | When therapeutic concentrations of [[furosemide]], [[propranolol]], [[dipyridamole]], [[warfarin]], [[quinidine]] or [[naproxen]] were added to human plasma (in vitro), the plasma protein binding of CARDENE was not altered.<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce141ca0-d734-11df-8537-0002a5d5c51b | title = CARDENE SR (nicardipine hydrochloride) capsule, extended release [EKR Therapeutics] | accessdate =}}</ref> | ||
==References== | |||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 16:21, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]
For patient information about Nicardipine, click here.
Drug Interactions
Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with CARDENE. The combination is well tolerated.
Cimetidine: Cimetidine increases CARDENE plasma levels. Patients receiving the two drugs concomitantly should be carefully monitored.
Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood. CARDENE usually does not alter the plasma levels of digoxin; however, serum digoxin levels should be evaluated after concomitant therapy with CARDENE is initiated.
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions were not seen during clinical studies with CARDENE, an increased volume of circulating fluids might be required if such an interaction were to occur.
Cyclosporine: Concomitant administration of nicardipine and cyclosporine results in elevated plasma cyclosporine levels. Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine or naproxen were added to human plasma (in vitro), the plasma protein binding of CARDENE was not altered.[1]